Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Chronic Kidney Disease Clinical Trial

— VEMAKD  

Official title:

Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02497300
• Other study ID #: F140508008
• Status: Completed
• Phase: Phase 2
• Start date: March 2015
• Est. completion date: July 2021

Study information

• Verified date: November 2022
• Source: University of Alabama at Birmingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vascular endothelial dysfunction increases cardiovascular (CV) risk and contributes to the progression of chronic kidney disease (CKD). Mineralocorticoid receptor (MR) antagonists have been shown to improve endothelial function, as well as decrease CV mortality and proteinuria. The specific biochemical pathways that produce these pharmacological effects for MR antagonists, however, are poorly understood. This study investigates the effect of MR antagonism on endothelial function in patients with moderate (stage III) CKD using a randomized, controlled trial. Three specific aims are proposed: Aim 1: To determine if spironolactone improves endothelial function as compared to amiloride in patients with stage III CKD; Aim 2: To determine if oxidative stress is associated with changes in endothelial function by spironolactone compared to amiloride in patients with stage III CKD; and Aim 3: To determine if endothelial dysfunction contributes to albuminuria in patients with stage III CKD. The clinical relevance is to improve understanding of the mechanisms of kidney function decline in CKD in order to develop interventions to delay or prevent dialysis, which would translate into alleviating patient suffering, caregiver burden, and health care costs.

Description:

Study participants with proteinuric, stage III CKD will be randomly assigned in a double-masked fashion to spironolactone 25mg daily or amiloride 5 mg daily for 6 weeks and then crossed over to the alternate study medication after a 1 month wash-out period. Vascular function will be assessed at baseline and the end of each 6 week treatment period by: 1) ultrasound guided flow-mediated dilation (FMD) of the brachial artery, 2) impedence cardiography, 3) pulse-wave velocity, 4) 24 hour ambulatory blood pressure monitoring, and 5) serum and urine biomarkers. Participants will undergo a total of 7 visits over 16-18 weeks; 3 of the 7 visits will involve vascular function testing.

A study visit where vascular function testing is to be performed will begin at 0800 in the morning and start with a vital sign assessment including height, weight, body fat percent, and left arm automated BP measurement followed by confirmation of fasting status and a brief past medical history. Each participant will then lie supine for 10 minutes in preparation for vascular function testing. Following the pulse wave velocity, impedence cardiography, and FMD measurements, the participant will have his/her blood and urine collected for laboratory testing. Laboratory testing will include ~20 mL of blood for plasma and serum testing. Participants will return 24 hour urine samples and have a 24 hour ambulatory monitor placed. This entire visit is expected to take 2 hours.

Study visits where vascular function testing will not be performed (e.g., screening visit, visit 2, visit 4, and visit 5; should last 30 minutes and involve a medication assessment, vital sign check, and blood collection for serum potassium (~4 mL of blood).

All study medication will be prepared by the the University of Alabama (UAB) Research Pharmacy in matching capsules and placed in pill bottles labeled "A" and "B". The order of medication dispensing will follow simple randomization using an a priori randomization list prepared by the research pharmacy. All study personnel with participant interaction are masked to the order of study medication.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 2021
• Est. primary completion date: July 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Adults (18-65 years of age)

• CKD (eGFR 25-60 mL/min/1.73m2) with urine albumin-to-creatinine ratio > 30 mg/g

• CKD (eGFR > 60 mL/min/1.73m2) with urine albumin-to-creatinine ratio = 300 mg/g

Exclusion Criteria:

• Severe hypertension (HTN) (office BP = 160/100 mm Hg)

• Hypotension (office BP < 110/70 mm Hg)

• Serum potassium > 5 milliequivalent/L

• History of arrhythmia, including atrial fibrillation

• Pregnant or breast feeding woman

• Diabetes mellitus (DM) type 1

• Diabetes mellitus type 2 with glycosylated hemoglobin = 6.5%

• Dementia or cognitive impairment prohibiting consent

• History of ischemic stroke, unstable angina, or myocardial infarction within the past 6 months

• Allergy or intolerance to spironolactone or amiloride

• Use of an MR antagonist or an epithelial sodium channel blocking medication within the last month

• Known primary aldosteronism or renal artery stenosis

Related Conditions & MeSH terms

• Albuminuria
• Chronic Kidney Disease
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Spironolactone

• Amiloride

Locations

Country	Name	City	State
United States	Hypertension Research Clinic at UAB	Birmingham	Alabama

Sponsors (2)

Lead Sponsor	Collaborator
University of Alabama at Birmingham	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in 24 Hour Ambulatory Systolic Blood Pressure	The study was not able to meet its recruitment goal, and participant numbers were too low to test the intended primary outcome of "Difference in percent change of ultrasound-guided flow-mediated dilation between 6 weeks of spironolactone vs. 6 weeks of amiloride." The change in 24hr ABPM systolic BP (Baseline - 6 week) is reported here.	6 weeks
Primary	Change in Oxidative Stress as Measured by Urine Levels of F2-isoprostanes	Difference in level of urine 8-iso-prostaglandin-F2-alpha per mg of creatinine levels between 6 weeks of spironolactone vs. 6 weeks of amiloride.	6 weeks
Primary	Change in Albuminuria	Change of the urine albumin-to-creatinine ratio (baseline - post-study med) after 6 weeks of spironolactone vs. 6 weeks of amiloride.	6 weeks
Secondary	Change in Serum Potassium	Difference in serum potassium levels (baseline - post-medication) after 6 weeks of spironolactone vs. 6 weeks of amiloride.	6 weeks
Secondary	Change in Serum Creatinine (Baseline - Post-medication)	Difference in serum creatinine (baseline - post-medication) after 6 weeks of spironolactone vs. 6 weeks of amiloride.	6 weeks